The diverse group of experts has developed a biorepository of patient - derived tissues, which will be used for testing investigational
drugs in preclinical models.
She has identified novel immune - modulating activities associated with targeted cancer
drugs in preclinical models, and developed synergistic immunotherapy combinations.
Not exact matches
In preclinical studies using cell models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published in PLOS ONE from the Perelman School of Medicine at the University of Pennsylvani
In preclinical studies using cell
models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering
drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published
in PLOS ONE from the Perelman School of Medicine at the University of Pennsylvani
in PLOS ONE from the Perelman School of Medicine at the University of Pennsylvania.
Developing therapies and testing
drugs using current
preclinical models have limitations
in reliability and predictability.
Several research institutions and companies have vaccine and
drug candidates nearly ready to test, but until now a mouse
model — a critical stage
in preclinical testing — has not been available.
«The novelty of this study is two-fold: We used a
preclinical prevention paradigm of a CRF - antagonist (a
drug that blocks the CRF receptor
in brain cells) called R121919
in a well - established AD
model — and we did so
in a way that draws upon our experience
in human trials.
The other study — Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents
in preclinical models of glioblastoma — published March 30, shows how
drugs targeting PI3K and MAPK could represent promising candidates for glioblastoma therapy.
«Future studies will aim to explore the relationship between SND1 and STAT3, identify additional microRNAs that may be relevant to malignant glioma and explore the effects of
drugs that block SND1 expression
in more advanced
preclinical models.»
«The
model for
preclinical studies to predict with great accuracy which
drugs would work
in the clinic was developed a decade ago,» says Dr. Chesi.
Our scientists engage with you
in the design and execution of your
preclinical drug development program using our AAALAC approved animal facilities, proprietary animal
models, and extensive capabilities.
P - glycoprotein mediated efflux limits substrate and
drug uptake
in a
preclinical brain metastases of breast cancer
model.
Having a strong R&D department with great experience and expertise
in drug development, animal
model and assay development and
preclinical efficacy evaluation, the contribution of Biomedcode has been greatly valued by our partners, as documented by our participation
in several collaborative research projects.
This
model offers unique capabilities for
preclinical assessment of thrombosis risk
in a patient - specific manner, including efficacy testing of anti-thrombotic agents, elucidation of mechanism of action, and, potentially, biomarker identification, all providing a much - needed platform for
drug discovery and development.
Recent approval from the U.S. Food and
Drug Administration to begin clinical studies was based on compelling activity upon IACS - 10759 treatment
in multiple
preclinical models of AML.
PHILADELPHIA —
In preclinical studies using cell models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published in PLOS One from the Perelman School of Medicine at the University of Pennsylvani
In preclinical studies using cell
models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering
drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published
in PLOS One from the Perelman School of Medicine at the University of Pennsylvani
in PLOS One from the Perelman School of Medicine at the University of Pennsylvania.
His research group actively collaborates with several pharmaceutical companies to provide valuable
preclinical data
in animal
models for their targeted
drugs.
Tags for this Online Resume: Business Development, CRO Services, Biologics, Small Molecules,
Preclinical Drug Development,
Drug Discovery,
In Vivo efficacy
models,
Preclinical R&D, ELISA, Cardiovascular, Cellular, Injections, Oncology, Research, Pharmaceutical, Business Development Manager, Cancer, Applications, Automation, Field Applications Scientist, Cell based assays